Video

Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian Cancer

Author(s):

Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.

Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.

The biggest challenge with risk-reducing salpingo-oophorectomy, Lu explains, is that BRCA1 patients in their mid- to late-30s and BRCA2 patients in their early-40s are being asked to undergo menopause 10 to 15 years earlier than they would normally experience it. Even with hormone replacement therapy, there still are significant changes made to their lives with these procedures. However, clinicians educate patients on all options, and explain that these procedures are still being evaluated with regards to efficacy and safety, Lu says.

In the prospective, nonrandomized, multicenter WISP study, this patient population at high risk for ovarian cancer chose either salpingectomy with delayed oophorectomy or risk-reducing salpingo-oophorectomy, and completed questionnaires at baseline and at 6 months. Patient-reported results showed that those who underwent either procedure had a significant decrease in cancer distress. However, those who had chosen risk-reducing salpingo-oophorectomy had a significant worsening of menopausal symptoms and an increase in decision regret compared with patients who underwent salpingectomy with delayed oophorectomy.

<<< 2019 SGO Annual Meeting

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.